Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Innovation - drugs and diagnostics.

Roger Finch1

  • 1Division of Microbiology and Infectious Diseases, Molecular Medical Sciences, Clinical Sciences Building, University of Nottingham and Nottingham University Hospitals NHS Trust, City Hospital Campus, Nottingham NG5 1PB, UK. r.finch@nottingham.ac.uk

The Journal of Antimicrobial Chemotherapy
|September 14, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Professor Francis William O'Grady, 7 November 1925-20 May 2015.

The Journal of antimicrobial chemotherapy·2016
Same author

Current challenges in antimicrobial resistance and healthcare-associated infections: role and organization of ARHAI.

The Journal of antimicrobial chemotherapy·2012
Same author

Fluoroquinolones in the treatment of severe community-acquired.

British journal of hospital medicine (London, England : 2005)·2012
Same author

Regulatory opportunities to encourage technology solutions to antibacterial drug resistance.

The Journal of antimicrobial chemotherapy·2011
Same author

Generic antibiotics, antibiotic resistance, and drug licensing.

The Lancet. Infectious diseases·2010
Same author

Antimicrobials: past, present and uncertain future.

Clinical medicine (London, England)·2009

Combating antibiotic resistance requires a global strategy focusing on surveillance, prudent prescribing, and new drug development. Declining antibiotic development, due to economic and regulatory hurdles, necessitates urgent action to bridge the technology gap.

Area of Science:

  • Microbiology
  • Public Health
  • Pharmacology

Background:

  • Antibiotic resistance is a significant global health challenge requiring multifaceted control strategies.
  • International organizations like the WHO advocate for surveillance, monitoring antibiotic use, and promoting new drug development.
  • A substantial decline in new antibiotic classes has occurred concurrently with rising resistance rates.

Purpose of the Study:

  • To address the critical technology gap in antibiotic resistance control.
  • To convene stakeholders to discuss and promote new technologies for combating antibiotic resistance.
  • To raise awareness among governments, academia, and industry regarding the challenges in antibiotic development.

Main Methods:

  • A European Union Intergovernmental Conference was organized to discuss antibiotic resistance and new technologies.

Related Experiment Videos

  • Delegates from academia, industry, funding agencies, and regulatory bodies participated.
  • Recommendations from the conference were published.

    • Main Results:

    • The conference highlighted the need to address the technology gap in antimicrobial resistance.
    • Multiple stakeholders engaged in discussions on promoting new technologies.
    • Published recommendations provide a roadmap for future actions.

    Conclusions:

    • Urgent action is needed to stimulate the development of new antimicrobial technologies.
    • Collaboration between various sectors is crucial for effective antibiotic resistance control.
    • Addressing economic and regulatory barriers is essential for antibiotic innovation.